These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
247 related items for PubMed ID: 11454672
1. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Tanner M, Järvinen P, Isola J. Cancer Res; 2001 Jul 15; 61(14):5345-8. PubMed ID: 11454672 [Abstract] [Full Text] [Related]
2. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. Scandinavian Breast Group Trial 9401Laboratory of Cancer Biology, Institute of Medical Technology, and Department of Oncology, Tampere University and Tampere University Hospital, Tampere, Finland., Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J. J Clin Oncol; 2006 Jun 01; 24(16):2428-36. PubMed ID: 16682728 [Abstract] [Full Text] [Related]
3. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases. Engelstaedter V, Schiffers J, Kahlert S, Mainka P, Engel J, Kirchner T, Diebold J, Mayr D. Diagn Mol Pathol; 2012 Jun 01; 21(2):77-83. PubMed ID: 22555090 [Abstract] [Full Text] [Related]
4. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Järvinen TA, Tanner M, Bärlund M, Borg A, Isola J. Genes Chromosomes Cancer; 1999 Oct 01; 26(2):142-50. PubMed ID: 10469452 [Abstract] [Full Text] [Related]
5. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients. Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, Yin PL, Chen M. Taiwan J Obstet Gynecol; 2007 Jun 01; 46(2):146-51. PubMed ID: 17638622 [Abstract] [Full Text] [Related]
6. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables. Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS. Mod Pathol; 2000 May 01; 13(5):542-7. PubMed ID: 10824926 [Abstract] [Full Text] [Related]
7. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD. Clin Cancer Res; 2002 Apr 01; 8(4):1061-7. PubMed ID: 11948114 [Abstract] [Full Text] [Related]
8. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H. Mod Pathol; 2002 Feb 01; 15(2):116-24. PubMed ID: 11850540 [Abstract] [Full Text] [Related]
10. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Gong Y, Booser DJ, Sneige N. Cancer; 2005 May 01; 103(9):1763-9. PubMed ID: 15786420 [Abstract] [Full Text] [Related]
11. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ. Clin Cancer Res; 2002 May 01; 8(5):1107-16. PubMed ID: 12006526 [Abstract] [Full Text] [Related]
12. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer. Bouchalová K, Trojanec R, Kolár Z, Cwiertka K, Cernáková I, Mihál V, Hajdúch M. Neoplasma; 2006 May 01; 53(5):393-401. PubMed ID: 17013533 [Abstract] [Full Text] [Related]
15. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Hengstler JG, Lange J, Kett A, Dornhöfer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, Tanner B. Cancer Res; 1999 Jul 01; 59(13):3206-14. PubMed ID: 10397267 [Abstract] [Full Text] [Related]
16. Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites. Durbecq V, Di Leo A, Cardoso F, Rouas G, Leroy JY, Piccart M, Larsimont D. Breast Cancer Res Treat; 2003 Feb 01; 77(3):199-204. PubMed ID: 12602919 [Abstract] [Full Text] [Related]
17. Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification. Vranic S, Frkovic-Grazio S, Lamovec J, Serdarevic F, Gurjeva O, Palazzo J, Bilalovic N, Lee LM, Gatalica Z. Hum Pathol; 2010 Nov 01; 41(11):1617-23. PubMed ID: 20688355 [Abstract] [Full Text] [Related]
18. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Mueller RE, Parkes RK, Andrulis I, O'Malley FP. Genes Chromosomes Cancer; 2004 Apr 01; 39(4):288-97. PubMed ID: 14978790 [Abstract] [Full Text] [Related]
19. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry. Meng H, Chen R, Li W, Xu L, Xu L. Pathol Int; 2012 Jun 01; 62(6):391-9. PubMed ID: 22612507 [Abstract] [Full Text] [Related]
20. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes. Menendez JA, Vellon L, Lupu R. Int J Mol Med; 2006 Dec 01; 18(6):1081-7. PubMed ID: 17089011 [Abstract] [Full Text] [Related] Page: [Next] [New Search]